Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
18 hedge funds and large institutions have $18.9M invested in Nexvet Biopharma plc Ordinary Shares in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less capital invested
Capital invested by funds: $19.7M → $18.9M (-$820K)
10% less funds holding
Funds holding: 20 → 18 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$908K |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$473K |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$45K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.42K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.57M |
| 2 |
Goldman Sachs
New York
|
-$60K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$44K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$6.3K |
| 5 |
NFG
Next Financial Group
Houston,
Texas
|
-$3.59K |
NVET Hedge Fund Activity: Q1 2016 in Review
18 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q1 2016, worth a combined $18.9M — down 4.2% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NVET and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Broadfin Capital, adding an estimated $908K. The largest seller was Wellington Management Group, exiting entirely with an estimated $1.57M sold.
- 18 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q1 2016, down from 20 in Q4 2015.
- Funds reported $18.9M of Nexvet Biopharma plc Ordinary Shares stock for Q1 2016, down 4.2% quarter-over-quarter.
- 1 fund opened new Nexvet Biopharma plc Ordinary Shares positions in Q1 2016 and 3 closed out, a net change of -2 holders.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q1 2016 was Broadfin Capital, an estimated $908K added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q1 2016 was Wellington Management Group, an estimated $1.57M sold.
Based on aggregated 13F filings for Q1 2016.